BONESUPPORT extended its U.S. distribution agreement with Zimmer Biomet (ZBH), continuing ZBH’s exclusive rights for CERAMENT BONE VOID FILLER products for orthopaedics, trauma and foot/ankle indications.
CERAMENT received its initial FDA 510(k) clearance in 2005, and the original distribution agreement with Biomet was signed in 2012. Presently, BONESUPPORT is enrolling patients into the FORTIFY Clinical Study, an FDA-approved IDE randomized control pivotal study for CERAMENT G antibiotic eluting product.
BONESUPPORT extended its U.S. distribution agreement with Zimmer Biomet (ZBH), continuing ZBH's exclusive rights for CERAMENT BONE VOID FILLER products for orthopaedics, trauma and foot/ankle indications.
CERAMENT received its initial FDA 510(k) clearance in 2005, and the original distribution agreement with Biomet was signed in 2012....
BONESUPPORT extended its U.S. distribution agreement with Zimmer Biomet (ZBH), continuing ZBH’s exclusive rights for CERAMENT BONE VOID FILLER products for orthopaedics, trauma and foot/ankle indications.
CERAMENT received its initial FDA 510(k) clearance in 2005, and the original distribution agreement with Biomet was signed in 2012. Presently, BONESUPPORT is enrolling patients into the FORTIFY Clinical Study, an FDA-approved IDE randomized control pivotal study for CERAMENT G antibiotic eluting product.
Copy to clipboard 
